Meeting NewsVideo

AI tool for NAFLD could ‘make biopsies history’

LOS ANGELES — In this video exclusive, Christos S. Mantzoros, MD, PhD, professor of medicine at Harvard Medical School, chief of endocrinology, diabetes and metabolism at the Boston VA Healthcare System and director of human nutrition at Beth Israel Deaconess Medical Center, discusses a new artificial intelligence and machine learning tool for nonalcoholic fatty liver disease prediction.

According to Mantzoros, the tool was designed to improve the detection and treatment of NAFLD and “make biopsies history.” Mantzoros shared promising results for sensitivity and specificity with the tool, which incorporates metabolomics, lipidomics and other factors to provide diagnoses and prognoses.

Watch the video for more.

LOS ANGELES — In this video exclusive, Christos S. Mantzoros, MD, PhD, professor of medicine at Harvard Medical School, chief of endocrinology, diabetes and metabolism at the Boston VA Healthcare System and director of human nutrition at Beth Israel Deaconess Medical Center, discusses a new artificial intelligence and machine learning tool for nonalcoholic fatty liver disease prediction.

According to Mantzoros, the tool was designed to improve the detection and treatment of NAFLD and “make biopsies history.” Mantzoros shared promising results for sensitivity and specificity with the tool, which incorporates metabolomics, lipidomics and other factors to provide diagnoses and prognoses.

Watch the video for more.

    See more from World Congress on Insulin Resistance, Diabetes and Cardiovascular Disease